Aprogen Medicines Inc. (KRX:007460)
South Korea · Delayed Price · Currency is KRW 304.00
+3.00 (1.00%)
Apr 3, 2026, 3:30 PM KST
Aprogen Medicines Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | - | - | -55,619 | -98,657 | -93,920 |
Depreciation & Amortization | 23,597 | 24,305 | 29,071 | 28,392 | 25,262 |
Loss (Gain) From Sale of Assets | 2,786 | 201.14 | -30.3 | 457.39 | - |
Asset Writedown & Restructuring Costs | 739.83 | 801.87 | 2,271 | 9,162 | 223.61 |
Loss (Gain) From Sale of Investments | -1,749 | -303 | -341.93 | 2,744 | 1,228 |
Loss (Gain) on Equity Investments | 39,375 | - | - | 1,489 | 9,543 |
Stock-Based Compensation | 1,152 | 1,718 | 1,613 | 707.67 | 2,445 |
Provision & Write-off of Bad Debts | 384.75 | 1,573 | -8.5 | -5,001 | - |
Other Operating Activities | 13,519 | 23,634 | -19,249 | -35,587 | -17,926 |
Change in Accounts Receivable | 3,558 | -207.69 | 1,749 | 3,395 | 778.84 |
Change in Inventory | -4,030 | 1,270 | -5,024 | -17,526 | -8,367 |
Change in Accounts Payable | -2,683 | -4,369 | -3,491 | -1,852 | 3,378 |
Change in Income Taxes | -222.7 | - | 217.8 | 935.78 | 770.88 |
Change in Other Net Operating Assets | 31,487 | 6,761 | -9,315 | -2,151 | -8,155 |
Operating Cash Flow | 107,914 | 55,384 | -58,156 | -113,491 | -84,740 |
Operating Cash Flow Growth | 94.85% | - | - | - | - |
Capital Expenditures | -8,994 | -12,671 | -25,514 | -19,610 | -34,392 |
Sale of Property, Plant & Equipment | 373.34 | 83.04 | 2,273 | 131.65 | 40.06 |
Cash Acquisitions | -5,080 | -127.87 | - | 39,940 | - |
Divestitures | 58,122 | 300 | - | 29,285 | - |
Sale (Purchase) of Intangibles | -11,931 | -10,473 | -29,371 | -5,209 | -474.06 |
Investment in Securities | -59,583 | -9,486 | 965.68 | 27,268 | 18,390 |
Other Investing Activities | -36,702 | -8,130 | 8,193 | -1,690 | -924.3 |
Investing Cash Flow | -63,795 | -40,504 | -43,452 | 70,172 | -12,790 |
Short-Term Debt Issued | 37,500 | 11,050 | 14,610 | 96,500 | 134,190 |
Long-Term Debt Issued | 158,835 | 36,350 | 96,546 | - | 30,845 |
Total Debt Issued | 196,335 | 47,400 | 111,156 | 96,500 | 165,035 |
Short-Term Debt Repaid | -12,300 | -11,350 | -40,110 | -7,500 | -27,000 |
Long-Term Debt Repaid | -82,560 | -12,967 | -8,481 | -1,873 | -30,220 |
Total Debt Repaid | -94,860 | -24,317 | -48,591 | -9,373 | -57,220 |
Net Debt Issued (Repaid) | 101,475 | 23,083 | 62,565 | 87,127 | 107,815 |
Issuance of Common Stock | - | 0.76 | 5,515 | 30.97 | 2,583 |
Repurchase of Common Stock | - | -0.1 | - | -15,791 | - |
Dividends Paid | -0.08 | - | - | - | - |
Other Financing Activities | 1,467 | 63,537 | 26,216 | -561.9 | -0 |
Financing Cash Flow | 102,941 | 86,621 | 94,296 | 70,804 | 110,398 |
Foreign Exchange Rate Adjustments | 1,497 | 352.04 | -72.93 | -309.07 | 4.05 |
Net Cash Flow | 7,987 | 1,477 | -7,385 | 27,176 | 12,872 |
Free Cash Flow | 98,920 | 42,713 | -83,669 | -133,101 | -119,132 |
Free Cash Flow Growth | 131.59% | - | - | - | - |
Free Cash Flow Margin | 83.85% | 28.45% | -55.57% | -169.88% | -453.05% |
Free Cash Flow Per Share | 332.54 | 165.47 | -354.27 | -657.66 | -687.14 |
Cash Interest Paid | 2,821 | 630.72 | 42.76 | 10,992 | 11,339 |
Cash Income Tax Paid | 2,921 | 220.01 | -2,128 | 3,291 | 398.92 |
Levered Free Cash Flow | -91,444 | -41,649 | -21,656 | -145,213 | 26,095 |
Unlevered Free Cash Flow | -88,467 | -41,019 | -21,261 | -139,022 | 39,697 |
Change in Working Capital | 28,110 | 3,454 | -15,862 | -17,199 | -11,594 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.